Programme

  1. Coffee and registration

    Claudio Mereu Moderator: Claudio Mereu
    EU Regulatory Partner, Joint Managing Partner, Fieldfisher LLP, Belgium
  2. Keynote

    Andrej Kobe Andrej Kobe
    DG Environment, Unit B.2 – Sustainable Chemicals, EU Commission, Belgium
  3. Session 1: Current practice for Reach substance evaluation
  4. ECHA overview of REACH substance evaluation

    Claudio Carlon Claudio Carlon
    Head of Unit – Hazard Assessment C3, European Chemicals Agency, Finland
  5. Industry case study: How to address a listing of your substance proactively

    Jonathan Crozier Jonathan Crozier
    Secretary General, Formacare, Sector Group of Cefic, Belgium
  6. MS perspective: Process, case studies and strategies

    Christian Unkelbach Christian Unkelbach
    Scientific Officer, Federal Institute for Occupational Health and Safety, Germany
  7. Refreshments and networking

  8. Achievements, challenges and recommendations from an NGO perspective

    • Survey of achievements under evaluation
    • Bottle-necks in the substance evaluation process
    • Member states’ lack of regulatory follow-up after substance evaluation
    Elise Vitali Elise Vitali
    Project Officer for Chemicals, European Environmental Bureau, Belgium
  9. Q&A and panel discussion:

    Based on experiences with a substance by substance approach what is working well and what could be further improved?

    Christian Unkelbach Christian Unkelbach
    Scientific Officer, Federal Institute for Occupational Health and Safety, Germany
    Jonathan Crozier Jonathan Crozier
    Secretary General, Formacare, Sector Group of Cefic, Belgium
    Claudio Carlon Claudio Carlon
    Head of Unit – Hazard Assessment C3, European Chemicals Agency, Finland
    Elise Vitali Elise Vitali
    Project Officer for Chemicals, European Environmental Bureau, Belgium
    Mariana Fernandes de Barros Mariana Fernandes de Barros
    REACH Manager, Cefic
  10. Lunch

  11. Session 2: Current Reach substance evaluation decisions and conclusions
  12. Regulatory follow-up to substance evaluation decisions and conclusions

    • Introduction
    • SEv decisions follow-up: how it works in FR / FR statistics / positive and negative points from FR experience / proposals for improvement
    • SEv conclusions follow-up: how it works in FR / FR statistics / positive and negative points from FR experience / proposals for improvement
    • Conclusion
    Michel Franz Michel Franz
    Reach Policy Officer, Chemicals Unit, Ministry for an Ecological and Solidary Transition, France
  13. The enforcement of substance evaluation decisions/conclusions

    Otilija Špūrienė Otilija Špūrienė
    Senior advisor, Environmental Protection Agency, Lithuania
  14. ECHA’s Board of Appeal decisions on substance evaluations

    ECHA Board of Appeal, Finland

  15. Challenging substance evaluation decisions before ECHA's Board of Appeal

    Claudio Mereu Claudio Mereu
    EU Regulatory Partner, Joint Managing Partner, Fieldfisher LLP, Belgium
  16. Refreshments and networking

  17. Q&A and panel discussion: The evolution of substance evaluation

    • How lessons learned from substance evaluations can inform future work
    • The role of ECHA’s Board of Appeal in substance evaluation
    • International dimension – what can we learn from global substance evaluation outcomes in the context of the SDG goals, substitution, and UN conventions?
  18. Session 3: Work in progress towards optimizing the process - assessment in groups of substances
  19. Industry experience with first combined compliance check - a pilot case that could define the model for the future of ECHA’s combined evaluation

    • The first time compliance check (CCH) and Substance Evaluation (SEv) take place in parallel 
    • The first time both processes take place on a group of metals 
    • The first time the SEv decisions were circulated to all registrants
    Caroline Braibant Caroline Braibant
    Secretary-General, International Antimony Association, Belgium
  20. Substance evaluation on groups of substances

    • How to address concerns for multiple substances by requesting further information on only a sub-set of substances in a group or a category
    Petra van Kesteren Petra van Kesteren
    Senior advisor REACH, Netherlands National Institute for Public Health and the Environment, The Netherlands
  21. Concerns about animal testing for substance evaluations

    • Animal testing principles under REACH
    • Mechanisms in REACH for avoiding testing on animals
    • Substance evaluation compared to dossier evaluation
    • Concerns about substance evaluation and testing on animals
    • Improvements following appeals
    • Scope for further improvements to substance evaluation
    • The future of REACH, obligations for testing only as a last resort and the promotion of alternative methods
    Emma Grange Emma Grange
    Senior Science Advisor – Regulatory Toxicology, Cruelty Free International, UK
  22. Q&A and panel discussion:

    • What do we need to generate information on a group of substances?
    • What are the implications for animal testing?
    • How can we make the grouping approach work between all the stakeholders? (communication, costs, etc)
  23. End of conference